109 related articles for article (PubMed ID: 24647772)
1. Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression.
Zhou JJ; Deng XG; He XY; Zhou Y; Yu M; Gao WC; Zeng B; Zhou QB; Li ZH; Chen RF
Int J Oncol; 2014 Jun; 44(6):2034-40. PubMed ID: 24647772
[TBL] [Abstract][Full Text] [Related]
2. TALEN-induced disruption of Nanog expression results in reduced proliferation, invasiveness and migration, increased chemosensitivity and reversal of EMT in HepG2 cells.
Yu AQ; Ding Y; Li CL; Yang Y; Yan SR; Li DS
Oncol Rep; 2016 Mar; 35(3):1657-63. PubMed ID: 26676719
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.
Shi Y; Wang SY; Yao M; Sai WL; Wu W; Yang JL; Cai Y; Zheng WJ; Yao DF
World J Gastroenterol; 2015 Dec; 21(45):12814-21. PubMed ID: 26668505
[TBL] [Abstract][Full Text] [Related]
5. Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK.
Shen C; Ka SO; Kim SJ; Kim JH; Park BH; Park JH
Tumour Biol; 2016 Aug; 37(8):11199-208. PubMed ID: 26939902
[TBL] [Abstract][Full Text] [Related]
6. siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin.
Alemohammad H; Motafakkerazad R; Asadzadeh Z; Farsad N; Hemmat N; Najafzadeh B; Vasefifar P; Baradaran B
Gene; 2022 May; 821():146333. PubMed ID: 35182674
[TBL] [Abstract][Full Text] [Related]
7. Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P‑glycoprotein expression.
Sun L; Chen W; Qu L; Wu J; Si J
Mol Med Rep; 2013 Dec; 8(6):1883-7. PubMed ID: 24145579
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of NPM reverses multidrug resistance in human hepatoma cells via inhibition of P-glycoprotein expression.
Luo F; Li H; Liang J; Jia H; Li X; Xiao H; He X; He J; Tian Y; Zhao H
Mol Med Rep; 2017 Apr; 15(4):2360-2368. PubMed ID: 28259962
[TBL] [Abstract][Full Text] [Related]
9. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Tsang WP; Kwok TT
Oncogene; 2007 Jul; 26(33):4877-81. PubMed ID: 17297456
[TBL] [Abstract][Full Text] [Related]
10. Reversal effect of Dioscin on multidrug resistance in human hepatoma HepG2/adriamycin cells.
Sun BT; Zheng LH; Bao YL; Yu CL; Wu Y; Meng XY; Li YX
Eur J Pharmacol; 2011 Mar; 654(2):129-34. PubMed ID: 21195709
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells.
Yahya SM; Hamed AR; Emara M; Soltan MM; Abd-Ellatef GE; Abdelnasser SM
Tumour Biol; 2016 May; 37(5):5925-32. PubMed ID: 26596829
[TBL] [Abstract][Full Text] [Related]
12. ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA.
Ma H; Yue X; Gao L; Liang X; Yan W; Zhang Z; Shan H; Zhang H; Spear BT; Ma C
Oncotarget; 2015 Jan; 6(2):1049-63. PubMed ID: 25473899
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
[TBL] [Abstract][Full Text] [Related]
14. Increased Nanog expression promotes tumor development and Cisplatin resistance in human esophageal cancer cells.
Yang L; Zhang X; Zhang M; Zhang J; Sheng Y; Sun X; Chen Q; Wang LX
Cell Physiol Biochem; 2012; 30(4):943-52. PubMed ID: 23221432
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.
Bourguignon LY; Peyrollier K; Xia W; Gilad E
J Biol Chem; 2008 Jun; 283(25):17635-51. PubMed ID: 18441325
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma.
Lai KP; Chen J; He M; Ching AK; Lau C; Lai PB; To KF; Wong N
Int J Cancer; 2014 Oct; 135(8):1790-9. PubMed ID: 24585547
[TBL] [Abstract][Full Text] [Related]
17. Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells.
Huang ZJ; You J; Luo WY; Chen BS; Feng QZ; Wu BL; Jiang L; Luo Q
Mol Med Rep; 2015 Mar; 11(3):1647-54. PubMed ID: 25405855
[TBL] [Abstract][Full Text] [Related]
18. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
Yan X; Zhao J; Zhang R
Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of hydro-alcoholic extract of Eclipta alba for its multidrug resistance reversal potential: an in vitro study.
Chaudhary H; Jena PK; Seshadri S
Nutr Cancer; 2013; 65(5):775-80. PubMed ID: 23859045
[TBL] [Abstract][Full Text] [Related]
20. Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells.
Zheng W; Sai W; Yao M; Gu H; Yao Y; Qian Q; Yao D
Tumour Biol; 2015 May; 36(5):3995-4003. PubMed ID: 25600802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
